2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

T cells

" in MedChemExpress (MCE) Product Catalog:

1044

Inhibitors & Agonists

2

Screening Libraries

28

Fluorescent Dye

114

Biochemical Assay Reagents

149

Peptides

6

MCE Kits

119

Inhibitory Antibodies

172

Natural
Products

2

Recombinant Proteins

17

Isotope-Labeled Compounds

7

Antibodies

6

Click Chemistry

27

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9947
    Efalizumab

    		Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
    Efalizumab
  • HY-P99392
    Teclistamab

    		CD3 Cancer
    Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
    Teclistamab
  • HY-144088
    ZYF0033

    HPK1-IN-22

    		 MAP4K Inflammation/Immunology Cancer
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a + CD8 + T Cells, PD-1 +CD8 + T Cells, TIM-3 +CD8 + T Cells LAG3< sup>+CD8 + T Cellular immersion decreases.
    ZYF0033
  • HY-131140
    BD750
    4 Publications Verification

    		 JAK STAT Inflammation/Immunology Cancer
    BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .
    BD750
  • HY-P99523
    Vepsitamab

    AMG 199

    		 CD3 Cancer
    Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
    Vepsitamab
  • HY-NP028
    Keyhole Limpet Hemocyanin-FITC

    KLH-FITC

    		 Biochemical Assay Reagents Fluorescent Dye Inflammation/Immunology
    Keyhole Limpet Hemocyanin-FITC induces both T-cell-dependent and T-cell-independent immune responses .
    Keyhole Limpet Hemocyanin-FITC
  • HY-W181026
    KLF10-IN-1

    		Others Inflammation/Immunology
    KLF10-IN-1 (#48-15) is a KLF10 inhibitor with an IC50 value of 40 μM for KLF10 reporter gene. KLF10-IN-1 can inhibit KLF10-DNA binding and transcriptional activity, block the conversion of CD4+CD25−T cells to CD4+CD25+T regulatory cells, and inhibit the expression of KLF10 target genes. KLF10-IN-1 can be used as a useful mechanistic probe to study KLF10-mediated effects and T regulatory cell biology .
    KLF10-IN-1
  • HY-169005
    Cbl-b-IN-27

    		Others Inflammation/Immunology
    Cbl-b-IN-27 is a casitas B-lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC50 value of 7 nM. Cbl-b-IN-27 is promising for research of effector T cell function, T cell, natural killer (NK) cell and B cell activation regulation .
    Cbl-b-IN-27
  • HY-119527
    Conagenin

    		Others Inflammation/Immunology Cancer
    Conagenin is an immunomodulator. Conagenin shows antitumor effects by activation of T cells and increasing antitumor effector cells .
    Conagenin
  • HY-P10417
    RTDLDSLRTYTL

    		Integrin Others Cancer
    RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
    RTDLDSLRTYTL
  • HY-126037
    (±)-ML 209
    1 Publications Verification

    		 ROR Inflammation/Immunology
    (±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 + T cells into other lineages, including Th1 and regulatory T cells .
    (±)-ML 209
  • HY-19486
    UR-1505

    		Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related Inflammation/Immunology
    UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27 KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .
    UR-1505
  • HY-P99390
    Tepoditamab

    MCLA 117

    		 CD3 Cancer
    Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
    Tepoditamab
  • HY-P99302
    Lulizumab

    Humanized Anti-CD28 Recombinant Antibody

    		 CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
    Lulizumab
  • HY-121662
    Lenaldekar

    LDK

    		 Apoptosis Inflammation/Immunology Cancer
    Lenaldekar (LDK) inhibits human and murine T-cell expansiomn. Lenaldekar inhibits autoimmune T cell response. Lenaldekar also induces cancer cell apoptosis. Lenaldekar can be used for T-cell mediated autoimmune diseases research .
    Lenaldekar
  • HY-P99617
    Fianlimab

    REGN3767

    		 LAG-3 Cancer
    Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
    Fianlimab
  • HY-P99387
    TSR-033

    		LAG-3 Cancer
    TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity .
    TSR-033
  • HY-148174
    JNJ-3790339

    		DGK Cancer
    JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective diacylglycerol kinase (DGKα) inhibitor with an IC50 of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation .
    JNJ-3790339
  • HY-161519
    PKM2 activator 7

    		Pyruvate Kinase Inflammation/Immunology
    PKM2 activator 7 (Compd B4) is a PKM2 activator with the AC50 of 0.144 μM. PKM2 activator 7 suppresses DSS (HY-116282C)-induced colitis by inhibiting T cell growth in mouse colitis model .
    PKM2 activator 7
  • HY-108161
    LF 1695

    		Interleukin Related Others
    LF 1695 is an immunomodulator. LF 1695 enhances the proliferative response of T cells by increasing the production of IL2 (interleukin-2) or the expression of the IL2 receptor. LF 1695 also increases CONA-induced inhibitory activity in human lymphocytes. LF 1695 can be used to study the proliferative and inhibitory activity of T cell subpopulations, as well as their role in immune regulation .
    LF 1695
  • HY-19344
    Lifitegrast
    4 Publications Verification

    SAR 1118; SHP-606

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast
  • HY-19344A
    Lifitegrast sodium
    4 Publications Verification

    SAR 1118 sodium; SHP-606 sodium

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .
    Lifitegrast sodium
  • HY-W019721
    Cyclosporin D

    		Nuclear Factor of activated T Cells (NFAT) Inflammation/Immunology
    Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A . Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc) .
    Cyclosporin D
  • HY-123531
    JNJ 10329670

    		Cathepsin Inflammation/Immunology
    JNJ 10329670 is a potent and selective noncovalent cathepsin S inhibitor with a Ki value of 34 nM for human cathepsin S. JNJ 10329670 blocks invariant chain proteolysis in B cells and dendritic cells, as well as antigen-induced T cell proliferation .
    JNJ 10329670
  • HY-165398
    Leucylleucine methyl ester

    		Others Others
    Leucylleucine methyl ester is a lysosomotropic agent that can be used to eliminate gamma delta T cells in human peripheral blood .
    Leucylleucine methyl ester
  • HY-141549
    BPK-21

    		Others Inflammation/Immunology
    BPK-21, an active acrylamide, suppresses T cell activation through blockade of ERCC3 function. BPK-21 specifically targets C342 in the helicase ERCC3 .
    BPK-21
  • HY-168010
    RC529-MDP

    		Toll-like Receptor (TLR) Interleukin Related NOD-like Receptor (NLR) Inflammation/Immunology
    RC529-MDP is an immunoadjuvant, combination of Toll-like Receptor (TLR) (TLR4a) and NOD-like Receptor (NOD2a), which enhances innate immune responses. BRC529-MDP activity depends on the TLR4 and NOD2 signaling pathways. RC529-MDP induces high levels of cytokine Interleukin Related (IL-6) in a mouse model, has immune-stimulating activity. RC529-MDP increases OVA-specific antibody responses, T cell responses, and the proportion of memory T cells in an OVA (HY-P0286)-injected mouse model .
    RC529-MDP
  • HY-119347
    Cirsilineol
    2 Publications Verification

    		 IFNAR STAT Inflammation/Immunology Cancer
    Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice .
    Cirsilineol
  • HY-19344R
    Lifitegrast (Standard)

    		Integrin Inflammation/Immunology
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast (Standard)
  • HY-156996
    AGI-134

    		Others Inflammation/Immunology Cancer
    AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis .
    AGI-134
  • HY-101309A
    5-(Nonyloxy)tryptamine oxalate

    		Others Cancer
    5-(Nonyloxy)tryptamine oxalate, a high-affinity agonist for the 5-HTIDβ receptor, with an ED50 value of 68 nM. 5-(Nonyloxy)tryptamine oxalate, exhibits antitumor growth activity in vivo and enhances the ability of T cells to target tumor cells .
    5-(Nonyloxy)tryptamine oxalate
  • HY-162501
    Yaddle1

    		Piezo Channel Inflammation/Immunology
    Yaddle1 (compound 34) a novel Piezo1 agonist, and induces Ca 2+ influx in human CD4 + T cell. Yaddle1 can be used for study of vaccine adjuvant .
    Yaddle1
  • HY-134932
    AA74-1

    		Others Inflammation/Immunology
    AA74-1 is a potent and selective inhibitor of APEH. AA74-1 significantly increases T cells proliferation by blocking the APEH activity .
    AA74-1
  • HY-W019721R
    Cyclosporin D (Standard)

    		Nuclear Factor of activated T Cells (NFAT) Inflammation/Immunology
    Cyclosporin D (Standard) is the analytical standard of Cyclosporin D. This product is intended for research and analytical applications. Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A . Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc) .
    Cyclosporin D (Standard)
  • HY-119347R
    Cirsilineol (Standard)

    		IFNAR STAT Inflammation/Immunology Cancer
    Cirsilineol (Standard) is the analytical standard of Cirsilineol. This product is intended for research and analytical applications. Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice .
    Cirsilineol (Standard)
  • HY-B0172A
    Isoallolithocholic acid
    2 Publications Verification

    3β-Hydroxy-5α-cholanic acid

    		 Others Inflammation/Immunology
    Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
    Isoallolithocholic acid
  • HY-163038
    Sulfamethoxazole-NO hydrate

    SMX-NO hydrate

    		 Others Inflammation/Immunology
    Sulfamethoxazole-NO (SMX-NO) hydrate is the reactive metabolite of SMX (HY-B0322). Sulfamethoxazole-NO (SMX-NO) hydrate actis as a typical hapten and is capable of covalently modifying the MHC-peptide complex, can stimulate hapten-reactive T cells .
    Sulfamethoxazole-NO hydrate
  • HY-B0078B
    Dacarbazine hydrochloride

    Imidazole Carboxamide hydrochloride

    		 Antibiotic Cancer
    Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma .
    Dacarbazine hydrochloride
  • HY-13624A
    Epirubicin hydrochloride
    20+ Cited Publications

    4'-Epidoxorubicin hydrochloride

    		 DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Cancer
    Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin hydrochloride
  • HY-13624
    Epirubicin

    4'-Epidoxorubicin

    		 DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Cancer
    Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin
  • HY-18555
    TMPA
    2 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A AMPK Metabolic Disease Inflammation/Immunology Cancer
    TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation .
    TMPA
  • HY-P99259
    Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    		 c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
    Cabiralizumab
  • HY-P99814
    Pavurutamab

    AMG-701

    		 CD3 Inflammation/Immunology Cancer
    Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
    Pavurutamab
  • HY-149213
    LSD1-IN-24

    		Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research .
    LSD1-IN-24
  • HY-143869
    HPK1-IN-28

    		MAP4K Cancer
    HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .
    HPK1-IN-28
  • HY-143870
    HPK1-IN-29

    		MAP4K Cancer
    HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .
    HPK1-IN-29
  • HY-155115
    LSD1-IN-27

    		Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .
    LSD1-IN-27
  • HY-77839
    Cortodoxone
    2 Publications Verification

    11-Deoxycortisol; cortexolone; Reichstein's substance S

    		 Glucocorticoid Receptor Endogenous Metabolite Inflammation/Immunology Endocrinology
    Cortodoxone (11-Deoxycortisol; cortexolone) is a glucocorticoid steroid hormone and also is a glucocorticoid antagonist. Cortodoxone increases tryptophan oxygenase (TO) activity and induces the secretion of corticosterone. Cortodoxone regulates T cell proliferation and activation .
    Cortodoxone
  • HY-123568
    PBI-1393

    BCH-1393

    		 Others Cancer
    PBI-1393 (BCH-1393) is an anticancer agent that enhances Th1 type cytokine production and primary T cell activation .
    PBI-1393
  • HY-146740
    PD-1/PD-L1-IN-27

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 + T cells and reduces T cell exhaustion .
    PD-1/PD-L1-IN-27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: